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Management of kidney transplant recipients (KTRs)
with suspected acute rejection (AR) ultimately relies on
kidney biopsy; however, noninvasive tests predicting
nonrejection would help avoid unnecessary biopsy.
AR involves recruitment of leukocytes avid for fluo-
rodeoxyglucose F18 (18F-FDG), thus 18F-FDG positron
emission tomography (PET) coupled with computed
tomography (CT) may noninvasively distinguish non-
rejection from AR. From January 2013 to February
2015, we prospectively performed 32 18F-FDG PET/CT
scans in 31 adult KTRs with suspected AR who
underwent transplant biopsy. Biopsies were catego-
rized into four groups: normal (n¼8), borderline
(n¼ 10), AR (n¼ 8), or other (n¼ 6, including 3 with
polyoma BK nephropathy). Estimated GFR was
comparable in all groups. PET/CT was performed
20118 minutes after administration of 3.20.2
MBq/kg of 18F-FDG, before any immunosuppression
change. Mean standard uptake values (SUVs) of both
upper and lower renal poles were measured. Mean
SUVs reached 1.5 0.2, 1.6 0.3, 2.9 0.8, and 2.2 1.2
for the normal, borderline, AR, and other groups,
respectively. One-way analysis of variance demon-
strated a significant difference of mean SUVs among
groups. A positive correlation betweenmean SUV and
acute composite Banff score was found, with r2¼ 0.49.
The area under the receiver operating characteristic
curve was 0.93, with 100% sensitivity and 50%
specificity using a mean SUV threshold of 1.6. In
conclusion, 18F-FDG PET/CT may help noninvasively
prevent avoidable transplant biopsies in KTRs with
suspected AR.
Abbreviations: 18F-FDG, fluorodeoxyglucose F18;
99mTc, technetium Tc 99m; ANOVA, analysis of vari-
ance; AR, acute rejection; CT, computed tomography;
KTR, kidney transplant recipient; PET, positron emis-
sion tomography; ROC, receiver operating characteris-
tic; SC, sulfur colloid; SUV, standard uptake value; VOI,
volume of interest
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Introduction
Kidney transplantation currently represents the best
available treatment for patients with end-stage renal
disease (1); however, its full benefits remain undermined
by acute rejection (AR), which may be cellular or antibody
mediated (2). Because immunosuppressive drugs treat AR
efficiently, an early diagnosis of such a reversible cause of
graft failure is essential. In clinical practice, the detection of
AR depends critically on assessments of serum creatinine,
an insensitive measure of renal injury (3). Ultimately, AR
diagnosis relies on renal transplant needle biopsy. Examin-
ing kidney samples provides well-characterized and gold
standard criteria for renal AR (4); however, such an invasive
procedure is associated with a significant risk of bleeding
and graft loss and is limited by sampling error and/or
interobserver variability (5,6). Moreover, repeated biopsies
to evaluate a renal graft’s status pose challenges, including
practicability and cost. Consequently, other sensitive and
less invasivemodalities, including gene expression profiling
and omic analyses of blood and urine samples as well as in
vivo imaging, are currently under investigation to reinforce
our clinical armamentarium for AR diagnosis (2,7–9).
Likewise, it would be useful to noninvasively predict
nonrejection in kidney transplant recipients (KTRs) with
acute renal dysfunction and suspected AR, thereby
avoiding unnecessary transplant biopsy.
Renal AR is associated with recruitment of activated
leukocytes into the transplant, and this process is at the
basis of the conventional Banff classification (10,11).
Activated leukocytes are characterized by high metabolic
activity and increased uptake of glucose analog fluorodeox-
yglucose F18 (18F-FDG), which can bemeasured by positron
emission tomography (PET) (12,13). Hence, 18F-FDG PET is
American Journal of Transplantation 2015; XX: 1–7
Wiley Periodicals Inc.
C Copyright 2015 The American Society of Transplantation
and the American Society of Transplant Surgeons
doi: 10.1111/ajt.13429
1
routinely used for detection, characterization, staging and
follow-up of inflammatory processes of various origins
(13,14). Moreover, the modern combination of PET with
computed tomography (CT) integrates both metabolic
and anatomical data and further helps localize and typify
tissue inflammation (14). Interestingly, experimental rodent
models of allogeneic kidney transplantation suggest that
18F-FDG PET/CTmay represent a novel option for detecting
renal AR noninvasively, specifically and early (15,16). In
the present pilot study, we prospectively assessed the
usefulness of 18F-FDG PET/CT imaging in KTRs presenting
with suspected AR who underwent a transplant needle
biopsy.
Patients and Methods
Patient population and specimens
The studywas approved by the institutional review board of theUniversity of
Liege (protocol B707201215598). After providing written informed consent,
KTRs undergoing a transplant biopsy for suspicion of AR (i.e., increase of
serum creatinine levels >30% of baseline value or delayed graft function)
(17) between January 2013 and February 2015 were prospectively enrolled.
Patients aged <18 years or who were pregnant or breastfeeding were
excluded. The management of the patients was based only on the results of
renal transplant biopsy and was at the discretion of the clinicians in charge.
No data from 18F-FDG PET/CT imaging were available at that time.
Histopathology
Biopsies were assessed by two pathologists blinded to the results of
18F-FDG PET/CT imaging and graded according to the latest Banff criteria
(11). Histological lesionswere scored as continuous variables (from 0 to 3) on
the basis of leukocyte infiltration severity in each component: glomeruli (g),
peritubular capillaries (ptc), arteries (v), tubules (t), and interstitium (i).
Biopsies diagnosed as normal were defined as having a Banff (iþ t) score<2
and no features of a disease process. Biopsies diagnosed as borderlinewere
defined as having a Banff (iþ t) score 2 (but <i2 t2 and v¼ 0), and no
feature of a specific disease process. Biopsies diagnosed as AR were
defined as having a Banff (iþ t) score i2 and t2 and/or v> 0. Biopsies
diagnosed as other were defined as showing features of a specific disease
process such as polyomavirus BK nephropathy or recurrent or de novo
glomerular diseases. All biopsies were stained for polyoma BK virus.
18F-FDG PET/CT imaging
The PET/CT procedure was performed using cross-calibrated Philips Gemini
TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland,
OH) at 201 18 minutes following intravenous injection of a mean dose of
3.2 0.2 MBq/kg of body weight of 18F-FDG. A low-dose helical CT (5-mm
slice thickness, 120-kV tube voltage, and 40-mAs tube current–time product)
centered to the renal transplant was performed, followed by PET scanning
with two bed positions, each lasting 240 seconds. Images were
reconstructed using iterative list mode time-of-flight algorithms. Corrections
for attenuation, dead time and random and scatter events were applied. The
PET/CT procedure was performed within a 48-hour period of the ultrasound-
guided renal transplant biopsy under fasting conditions and without
administration of contrast agent or diuretics. All 18F-FDG PET/CT scans
were done before any modification of immunosuppressive regimens. PET/
CT images were read independently by two experienced nuclear medicine
physicians blinded to the results of renal transplant biopsies. Four volumes
of interest (VOIs) of 1ml were drawn in the cortical region of both upper
(n¼ 2) and lower (n¼ 2) poles of the renal transplant, at distance from the
pelvicalyceal zone (Figure S1). Additional VOIs were drawn in the lumen of
the abdominal aorta (1ml) and the left psoas muscle (20ml), which are
classically considered as regions of homogeneous baseline 18F-FDG activity.
The maximal and mean standard uptake values (SUVs) were measured for
each VOI,with no threshold activity, using the following formula: (voxel value
in bequerels per milliliter patient weight in kilograms) / (injected dose in
bequerels1000 gm/kg).
Statistics
Data were expressed as mean 1 standard deviation and as median
(minimum–maximum). One-way analysis of variance (ANOVA) and Student t
tests were performed appropriately using MedCalc software (MedCalc,
Mariakerke, Belgium) to statistically compare mean SUVs among groups. A
p value <0.05 was considered statistically significant. The correlations
between mean SUV and acute composite (gþ iþ tþ vþ ptc) Banff scores
were performed using MedCalc. Histological lesions were scored as
continuous variables (from 0 to 3) on the basis of leukocyte infiltration
severity in each component. The receiver operating characteristic (ROC)
curve was drawn using MedCalc to discriminate AR group biopsies from
nonpathological (normal and borderline groups) biopsies. Sensitivity and
specificity were extrapolated from this ROC curve, targeting sensitivity as
close to 1 as probable.
Results
From January 2013 to February 2015, 32 18F-FDG PET/CT
scans were performed in 31 KTRs presenting with
suspected renal AR, including two with delayed graft
function (17). All participants underwent a renal transplant
biopsy as part of conventional medical management.
Clinical and biological characteristics of the cohort at the
time of biopsy are summarized in Table 1. Biopsies were
diagnosed as normal, borderline, AR, and other in 8, 10, 8,
and 6 cases, respectively. AR was antibody mediated in
only one case, whereas types 1, 2, and 3 cellular AR were
found in 5, 1, and 1 case, respectively. The causes of graft
failure in the other group included immune-allergic intersti-
tial nephropathy (n¼ 1), polyomavirus BK nephropathy
(n¼3), and glomerulonephritis (n¼2). One-way ANOVA
did not show any difference in estimated GFR between
groups of patients (p¼ 0.31) (Table 1).
PET/CT imaging was performed within 201 18 minutes
after intravenous administration of 3.2 0.2 MBq/kg of
body weight of 18F-FDG (Figure 1). Mean glycemia at the
time of 18F-FDG injectionwas 100.818.4mg/dl. OnePET/
CT procedure was not interpretable because of paravenous
injection of 18F-FDG. The mean cumulative exposure dose
for PET/CT imaging was 5.41 0.79mSv. Themean values
of SUV from four renal cortical VOIs reached 1.50.2,
1.6 0.3, 2.9 0.8, and 2.2 1.2 in histopathological
categories normal, borderline, AR, and other, respectively
(Figure 2A). One-way ANOVA demonstrated a significant
difference in mean SUVs among groups (p< 0.01). The
mean SUV of biopsy-proven AR was significantly higher
than that for normal cases (p<0.01). There were no
significant differences between biopsies with normal
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versus borderline or AR versus other histopathology.
Similar observations were made using either maximal
SUV from four renal cortical VOI or SUV ratios to aorta or
psoas muscle activity (data not shown). Statistical analyses
highlighted a positive correlation between mean SUVs and
acute composite Banff histological score (r2¼ 0.49,
p< 0.0001) (Figure 2B). Furthermore, increasing grades
(from i0 to i3) of leukocyte infiltration in renal allograft
interstitium were associated with increasing mean SUVs
(from 1.6 0.3 to 2.9 1.1, p< 0.05) (Figure 2C).
To further assess the usefulness of 18F-FDG PET/CT in
clinical practice, we statistically evaluated the threshold
of mean SUVs that would discriminate nonrejection.
Indeed, the majority of patients with normal histology or
borderline infiltrates will not progress into rejection,
whereas instant immunosuppression adjustments are
needed in cases of AR (18). Conversely, the diagnosis
procedure is specific when polyomavirus BK nephropathy
or glomerular diseases are suspected in cases of acute
renal failure in KTRs. Consequently, the ROC curve was
drawn after distinguishing biopsy-proven AR from normal
and borderline histopathology and showed an area under
the curve of 0.93 (p< 0.0001). Sensitivity and specificity
of 18F-FDG PET/CT in diagnosing AR were 100% and
50%, respectively, with a mean SUV threshold of 1.6
(Figure 3). In our cohort, characterized by a 25%
prevalence of biopsy-proven AR, the corresponding
negative and positive predictive values were 100% and
43.75%, respectively.
Discussion
In the present cohort of 32 18F-FDG PET/CT procedures
performed in 31 KTRs presenting with suspected AR,
biopsy-proven AR was characterized by significantly higher
18F-FDG uptake in the renal transplant cortex in comparison
to normal biopsies. Mean SUV appeared to be significantly
correlated with the severity of leukocyte infiltrates, as
assessed by conventional Banff score. Finally, ROC curve
analyses suggested that a mean SUV threshold of 1.6
discriminates nonrejection with a negative predictive value
of 100%. The poor specificity of 18F-FDG PET/CT in
detecting AR is primarily due to the nature of the
radiotracer.











Recipient Age (years) 43 (14–66) 25 (20–63) 35 (15–66) 54 (21–66) 57 (43–59) 0.11
Sex, male/female 24/8 6/2 10/0 4/4 4/2 0.10
BMI (kg/m2) 24 5 25 4 24 5 256 29 8 0.49
Dialysis vintage (days) 643 (0–3108) 45 (0–957) 511 (0–2480) 778 (0–3108) 864 (94–1849) 0.06
PRA maximum (n),
<5%/5%–84%/85%
29/2/1 8/0/0 10/0/0 5/2/1 6/0/0 0.13
Donor Donor type (n), DBD/DCD/LD 20/6/6 5/1/2 5/1/4 7/1/0 3/3/0 0.11
Age (years) 40 (15–65) 33 (25–57) 36 (15–65) 38 (20–58) 46 (15–62) 0.80
Sex, male/female 15/17 6/2 3/7 3/5 3/3 0.26
BMI (kg/m2) 25 5 28 6 24 4 231 26 7 0.21
Transplantation Rank (n), first/second 27/5 5/3 9/1 7/1 6/0 0.23
Cold ischemic time (min) 585 358 636 394 392 332 798 274 552 349 0.11
HLA mismatches
A 0.9 0.6 0.5 0.5 1.1 0.6 1.0 0.5 0.8 0.4 0.12
B 1.3 0.6 1.0 0.8 1.3 0.5 1.5 0.5 1.4 0.5 0.40
DR 0.9 0.7 0.6 0.7 1.1 0.6 0.6 0.7 1.2 0.4 0.20
Early graft function,
immediate/slow/delayed





CNI, CsA/FK/none 4/27/1 1/7/0 2/8/0 1/6/1 0/6/0 0.61
Antimetabolite,
MMF/MPA/Aza/none
22/7/1/2 5/2/1/0 7/3/0/0 7/0/0/1 3/2/0/1 0.45
mTOR inhibitor, yes/no 1/31 0/8 0/10 1/7 0/6 0.37
Steroids, yes/stop 25/7 7/1 5/5 7/1 6/0 0.07
Duration of KTx at biopsy (days) 199 (6–5524) 96 (9–5524) 1058 (64–3330) 305 (7–1748) 198 (66–1150) 0.20
eGFR MDRD (mL/min/1.73m2) 40.2 15.5 37.2 15.9 47.3 15.9 38.7 16.2 32.7 10.9 0.31
Data are expressed as mean 1 standard deviation and as median (minimum–maximum). Aza, azathioprine; BMI, body mass index; CNI, calcineurin inhibitor;
CsA, cyclosporin A; DCD, donor after circulatory death; DBD, donor after brain death; eGFR MDRD, estimated glomerular filtration rate according to the
Modification of Diet in Renal Disease formula; FK, tacrolimus; KTx, kidney transplantation; LD, living donor;MMF,mycophenolatemofetyl;MPA,mycophenolic
acid; mTOR, mammalian target of rapamycin; PRA, panel reactive antibody.
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Using radionuclides to image AR is not new and has been
performed previously with radiolabeled sulfur colloid (SC)
and fibrinogen as well as gallium citrate Ga 67. Comparative
meta-analysis suggested a similar specificity of graft labeling
during rejection using either radiotracer (19). Still, in clinical
settings within the permissible radiation dose, technetium
Tc99m (99mTc) SCappeared tobetter discriminateARon the
basis of a strictly visual scale (9). Unfortunately, several
studies using computer-assisted quantification of 99mTc SC
uptake by the allograft in comparison to the surrounding
pelvis showed conflicting results, with false-negative and
-positive rates that were too high tomake 99mTc SC useful in
predicting renal AR (20). PET/CT using the glucose analog
18F-FDG has been also proposed for the detection of renal
transplant AR in experimental rodent models of allogeneic
kidney transplantation (8,15). Inflammatory cells are charac-
terized by a high metabolic status and increased uptake of
18F-FDG (13). The advantages of 18F-FDG PET/CT are rapid
imaging, high target:background ratio and direct coregistra-
tion with low-dose CT without radiologic contrast medium
administration (14). 18F-FDG PET/CT can be used safely in
patients with renal function including normal to mildly
reduced GFR and end-stage renal disease. In rats, the renal
clearance of 18F-FDG does not correlate with renal function
(15). In particular, acute kidney injury secondary to cyclo-
sporin exposure or ischemia–reperfusion is not associated
with significant elevation of renal 18F-FDG accumulation.
There is a surprising gap of knowledge in the literature
concerning the impact of acute or chronic kidney injury on
renal 18F-FDG uptake in humans. In 2007, Minamimoto et al
investigated the influence of renal function on 18F-FDG
distribution and uptake in 20 healthy volunteers and 20
patientswith suspected renal failure (21). Regionsof interest
were placed over 15 different regions throughout the body,
including the left kidney. No significant difference was
observed in renal mean SUVs between healthy volunteers
and patients with suspected renal failure. In our series, no
difference in estimated GFRs was observed between
groups of patients categorized based on kidney histology.
Limitations of 18F-FDG PET/CT imaging include its relatively
high cost and restricted availability as well as patient
exposure to radiation originating from both PET and CT
procedures. Still, a cumulative exposure dose of 5.41 0.79
mSv, asobserved in this study, remains low incomparison to
other classical radiological examinations, such as thorax CT
(7mSv), abdomen CT (8 mSv), or coronary angiography
(16mSv) (22). Uptake of 18F-FDG is not specific for
inflammation and may be increased in other conditions
such as tumors or infections (12,23). Furthermore, physio-
logical urinary excretion of 18F-FDG may hamper the
measurement of 18F-FDG uptake in the renal parenchyma
(24). To overcome this problem and, eventually, to improve
the background:noise ratio, we administered aminimal dose
of 18F-FDG and performed late acquisitions. PET/CT images
were acquired within 201 18 minutes after intravenous
administration of 3.2 0.2 MBq/kg of body weight of the
radiotracer. In addition, multiple VOIs were drawn in the
renal transplant area, and a mean SUV was considered for
statistical analyses. We must admit that we were unable to
clearly differentiate the activity of renal parenchyma into
medulla- and cortex-related tissue activity. The VOIs were
located beneath the renal capsule away from the urinary
pelvis, which most probably corresponds to the cortex area.
The use ofmultiple independent VOIs distributed in both the
upper and lower renal poles aimed to avert sampling error,
which represents amain limitation of transplant biopsy (5,6).
Furthermore, assessing 18F-FDG activity in cross-sections
by image segmentation software (currently under develop-
ment and validation)might be another option tominimize the
sampling error. Similarly, dynamic or dual/multipoint analysis
of 18F-FDG PET/CT imaging may be an interesting way to
Figure 1: Representative 18F-FDG PET/CT imaging in kidney
transplant recipients with suspected acute rejection. PET (left
column), CT (middle column), and combined PET/CT images taken
after administration of 18F-FDG are shown for kidney transplant
recipients with biopsies showing normal histology, borderline
changes, acute rejection or polyomavirus BK nephropathy. The
arbitrary scale of SUVs (from 0 to 5) is illustrated on the right side.
18F-FDG, fluorodeoxyglucose F18; CT, computed tomography;
PET, positron emission tomography; SUV, standard uptake value.
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help differentiate between the different pathologies in KTRs
presenting with suspected AR (25).
The mean SUV of borderline biopsies was not statistically
different from that of normal biopsies, a finding that is in line
with recent comparative molecular phenotyping by micro-
array profiles (26). Similarly, themean SUV of biopsy-proven
AR was not statistically different from that of biopsies
showing alternative causes of acute graft dysfunction,
including glomerulonephritis and polyomavirus BK nephrop-
athy. The diagnosis procedure, however, is specific when
polyomavirus BK nephropathies or glomerular diseaseswith
proteinuria are suspected in cases of acute renal failure in
KTRs. The emergence of polyomavirus BK nephropathy
coincided with the advent of potent immunosuppressive
therapy (27). BK virus infection can occur under all
combinations of immunosuppressive therapy, and the
beneficial effects of antiviral agents remain unclear. Graft
survival in patientswithBKvirus nephropathy is poor (28).No
standardized protocol currently exists for the management
of BK viruria or viremia or established BK virus nephropathy.
Current clinical practice focuses on screening for BK virus
replication in urine and/or blood specimens and preemptive
reduction of immunosuppression in viremic patients (29).
The Banff Working Proposal 2009, based on viral load and
acute tubular injury instead of interstitial inflammation, does
not appear to be superior to alternative schemas assessing
renal inflammation (30). In our cohort, mean SUV significant-
ly correlated with the severity of graft inflammation and
leukocyte infiltration (r2¼ 0.49). Furthermore, the Banff
score for leukocyte infiltration in renal interstitium was
statistically associated with increasing values of mean graft
SUV. The 18F-FDG PET/CT pattern, however, was unable to
identify the cause of graft inflammation and dysfunction.
Ultimately, this determination relies on transplant biopsy
examination. Thesmall numberofpatientsdidnot allowus to
compare the uptake of 18F-FDG in cellular versus antibody-
mediated AR or in cases of chronic allograft failure. None of
the 32 renal transplant biopsies performed in our study
showed acute tubular necrosis (ATN). Because no study has
investigated the renal uptake of 18F-FDG in cases of ATN in
human patients, we must admit that we do not know how
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Figure 2: Statistical analyses of fluorodeoxyglucose F18 positron emission tomography and computed tomography imaging in
kidney transplant recipients with suspected acute rejection. (A) Mean SUVs in kidney transplant recipients with biopsies showing
normal histology (n¼8), borderline changes (n¼10), AR (n¼7), or other diagnostics (n¼6). p<0.01 between normal and AR.
(B) Correlation study betweenmeanSUV in renal transplant and acute composite Banff score. (C)Mean SUVs in kidney transplant recipients
with biopsies showing increasing Banff score of leukocyte infiltration in the interstitium: grade 0 (n¼13), grade 1 (n¼7), grade 2 (n¼4), and
grade 3 (n¼7). p<0.05 between grade 0 and grade 3. AR, acute rejection; SUV, standard uptake value.
AUC = 0.93 
p < 0.0001 













100 - Speciﬁcity 
Figure 3: ROC curve using fluorodeoxyglucose F18 positron
emission tomography and computed tomography imaging in
kidney transplant recipients with suspected acute rejection.
The ROC curve was drawn after discriminating kidney transplant
recipients with biopsies showing or not showing (ie, normal and
borderline histology) acute rejection. ROC, receiver operating
characteristic.
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On the basis of this pilot study, we postulate that 18F-FDG
PET/CT imaging may help selected patients avoid undergo-
ing renal transplant biopsy. Our observations are prelimi-
nary, given the small number of events and the absence of
prospective validation of a mean SUV threshold. Still, the
negative predictive value of 18F-FDGPET/CT imagingwith a
mean SUV threshold at 1.6 reaches 100%, thereby
significantly discriminating nonrejection in KTRs presenting
with suspected AR. Consequently, transplant needle
biopsies may be limited to KTRs in whom 18F-FDG SUV
exceeds this threshold. In our series, nine transplant
biopsies (28.1%) showing normal (n¼4) or borderline
(n¼5) histology were associated with a mean SUV inferior
to 1.6. Validation cohorts and additional large prospective
series are needed to further test whether a mean SUV
threshold for 18F-FDG-PET/CT imaging, in combinationwith
blood and urinary biomarkers (2,7), may help dictate the
need for transplant biopsy in KTRs presenting with
suspected AR.
Acknowledgments
The authors cordially thank the surgeons (M. Meurisse, C. Coimbra
Marques, A. De Roover, O. Detry, E. Hamoir, P. Honore, L. Kohnen, N.
Meurisse, and J-P Squifflet), the physicians (L. Vanovermeire and P.
Xhignesse), and the members of the local transplant coordination center
(MmeM-HDelbouille,M-HHans, JMornard) for their commitment to kidney
transplantation at the University of Liege Hospital in Liege, Belgium. We are
grateful to P. Delanaye, and C. Ricour for their help with statistical analyses.
FJ is a Fellow of the Fonds National de la RechercheScientifique (Research
Credit 3309), and received support from the University of Liege
(FondsSpeciaux a la Recherche) and from the Fonds Leon Fredericq, as
well as from the Royal Academy of Medicine of Belgium (Prix O. Dupont).
Disclosure
The authors of this manuscript have no conflicts of interest
to disclose as described by the American Journal of
Transplantation.
References
1. Tonelli M, Wiebe N, Knoll G, et al. Systematic review: Kidney
transplantation compared with dialysis in clinically relevant out-
comes. Am J Transplant 2011; 11: 2093–2109.
2. Suthanthiran M, Schwartz JE, Ding R, et al. Urinary-cell mRNA
profile and acute cellular rejection in kidney allografts. N Engl JMed
2013; 369: 20–31.
3. Thomas ME, Blaine C, Dawnay A, et al. The definition of acute
kidney injury and its use in practice. Kidney Int 2015; 87: 62–73.
4. WilliamsWW, Taheri D, Tolkoff-Rubin N, Colvin RB. Clinical role of
the renal transplant biopsy. Nat Rev Nephrol 2012; 8: 110–121.
5. Furness PN, Taub N. International variation in the interpretation of
renal transplant biopsies: Report of the CERTPAP Project. Kidney
Int 2001; 60: 1998–2012.
6. Azancot MA, Moreso F, Salcedo M, et al. The reproducibility and
predictive value on outcome of renal biopsies from expanded
criteria donors. Kidney Int 2014; 85: 1161–1168.
7. Ong S, Mannon RB. Genomic and proteomic fingerprints of acute
rejection in peripheral blood and urine. Transplant Rev (Orlando)
2015; 29: 60–67.
8. Pawelski H, Schnockel U, Kentrup D, Grabner A, Schafers M,
Reuter S. SPECT- and PET-based approaches for noninvasive
diagnosis of acute renal allograft rejection. BioMed Res Int 2014;
2014: 874785.
9. Einollahi B, Bakhtiari P, Simforoosh N, et al. Renal allograft
accumulation of technetium-99m sulfur colloid as a predictor of
graft rejection. Transplant Proc 2005; 37: 2973–2975.
10. SarwalM, ChuaMS, KambhamN, et al.Molecular heterogeneity in
acute renal allograft rejection identified by DNA microarray
profiling. N Engl J Med 2003; 349: 125–138.
11. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report:
Inclusion of c4d-negative antibody-mediated rejection and anti-
body-associated arterial lesions. Am J Transplant 2014; 14: 272–
283.
12. Jouret F, Lhommel R, Beguin C, et al. Positron-emission computed
tomography in cyst infection diagnosis in patients with autosomal
dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;
6: 1644–1650.
13. Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of unknown
origin: The role of 18F-FDG PET/CT. J Nucl Med 2008; 49: 1980–
1985.
14. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT:
EANMprocedure guidelines for tumour imaging: Version 2.0. Eur J
Nucl Med Mol Imaging 2015; 42: 328–354.
15. Reuter S, Schnockel U, Schroter R, et al. Non-invasive imaging of
acute renal allograft rejection in rats using small animal F-FDG-PET.
PLoS One 2009; 4: e5296.
16. Grabner A, Kentrup D, Schnockel U, et al. Non-invasive imaging of
acute allograft rejection after rat renal transplantation using 18F-
FDG PET. J Vis Exp 2013: e4240.
17. Mallon DH, Summers DM, Bradley JA, Pettigrew GJ. Defining
delayed graft function after renal transplantation: Simplest is best.
Transplantation 2013; 96: 885–889.
18. Beimler J, Zeier M. Borderline rejection after renal transplanta-
tion-to treat or not to treat. Clin Transplant 2009; 23(Suppl 21):
19–25.
19. George EA, Codd JE, Newton WT, Haibach H, Donati RM.
Comparative evaluation of renal transplant rejection with radio-
iodinated fibrinogen 99mTc-sulfur collid, and 67Ga-citrate. J Nucl
Med 1976; 17: 175–180.
20. Smith SB, Wombolt DG. Histologic correlation of transplant
rejection diagnosed by computer-assisted sulfur colloid scan.
Urology 1983; 21: 151–153.
21. Minamimoto R, Takahashi N, Inoue T. FDG-PET of patients with
suspected renal failure: Standardized uptake values in normal
tissues. Ann Nucl Med 2007; 21: 217–222.
22. Mettler FA Jr, HudaW, Yoshizumi TT, Mahesh M. Effective doses
in radiology and diagnostic nuclear medicine: A catalog. Radiology
2008; 248: 254–263.
23. Barrington SF,Mikhaeel NG, Kostakoglu L, et al. Role of imaging in
the staging and response assessment of lymphoma: Consensus of
the International Conference on Malignant Lymphomas Imaging
Working Group. J Clin Oncol 2014; 32: 3048–3058.
24. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von
Schulthess GK. Whole-body PET: Physiological and artifactual
fluorodeoxyglucose accumulations. J Nucl Med 1996; 37: 441–
446.
25. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18
fluorodeoxyglucose positron emission tomography: A potential
method to differentiate malignancy from inflammation and
Lovinfosse et al
6 American Journal of Transplantation 2015; XX: 1–7
normal tissue in the head and neck. Eur J Nucl Med 1999; 26:
1345–1348.
26. de Freitas DG, Sellares J, Mengel M, et al. The nature of biopsies
with ‘‘borderline rejection’’ and prospects for eliminating this
category. Am J Transplant 2012; 12: 191–201.
27. Pham PT, Schaenman J, Pham PC. BK virus infection following
kidney transplantation: An overview of risk factors, screening
strategies, and therapeutic interventions. Curr Opin Organ
Transplant 2014; 19: 401–412.
28. Masutani K. Current problems in screening, diagnosis and
treatment of polyomavirus BK nephropathy. Nephrology 2014;
19(Suppl 3): 11–16.
29. Costa C, Cavallo R. Polyomavirus-associated nephropathy.World J
Transplant 2012; 2: 84–94.
30. Masutani K, Shapiro R, Basu A, Tan H, WijkstromM, Randhawa P.
The Banff 2009Working Proposal for polyomavirus nephropathy: A
critical evaluation of its utility as a determinant of clinical outcome.
Am J Transplant 2012; 12: 907–918.
Supporting Information
Additional Supporting Information may be found in the
online version of this article.
Figure S1: Representative analysis a fluorodeoxyglu-
cose F 18 positron emission tomography and comput-
ed tomography image in a kidney transplant recipient
with suspected acute rejection. Four 1-ml VOIs (white
circles) are drawn in the cortex area of both upper and lower
poles of the renal transplant. Maximal and mean standard
uptake values (SUVs) are independently measured in each
VOI. In the present case, maximal SUVs in VOIs 1–4 were
1.88, 1.71, 1.52 and 1.55, respectively, whereas mean
SUVs in VOIs 1–4 were 1.41, 1.32, 1.44, and 1.41,
respectively. The biopsy of this patient showed normal
histology. VOI, volume of interest.
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